Celcuity (CELC) Earnings Date & Reports

Key Takeaways

• Celcuity is expected to report its third quarter 2026 results (period ending September 30, 2026) in mid-November, marking the first quarter in which its newly approved breast cancer drug, REVTORPYK, has begun generating commercial revenue.
• Wall Street consensus points to a net loss of roughly $1.45 per share, a wider loss than the $0.92 per share reported a year earlier, reflecting a sharp ramp in launch-related spending.
• Revenue estimates vary widely — from roughly $3 million to $7 million — underscoring uncertainty about how quickly the initial product launch will convert into recorded sales.
• Investors will focus on early launch uptake, selling, general and administrative (SG&A) expense growth, and updated commentary on the supplemental approval path for PIK3CA-mutant patients.
• Prostate cancer trial data expected later in the fourth quarter is a separate catalyst to monitor beyond the headline numbers.

Earnings Context and Why It Matters

Celcuity (CELC) is a biotechnology company that has spent years developing gedatolisib, a targeted therapy for advanced breast cancer, now commercialized under the brand name REVTORPYK. After receiving U.S. Food and Drug Administration (FDA) approval with Priority Review in 2026, the company transitioned from a pre-revenue, clinical-stage developer into a commercial-stage organization. This quarter's report is pivotal because it represents the first full look at the launch economics. For investors, the report will signal whether initial demand is materializing, how aggressively management is spending to build its sales force and payer relationships, and whether the company's substantial cash position is being deployed efficiently. Given the stock's history of sharp post-earnings moves, expectations heading into the release are elevated.

Earnings Expectations

Analysts expect Celcuity to report a net loss of approximately $1.45 per share for the third quarter of 2026, compared with a net loss of $0.92 per share in the same period last year. The widening loss is expected even as the company records its first meaningful product revenue, because commercial launch costs and continued research and development (R&D) investment are rising faster than early sales. Consensus revenue estimates are unusually dispersed, ranging from about $3 million to $7 million, reflecting the difficulty of forecasting the pace of an initial oncology launch.

Historically, Celcuity has beaten consensus estimates in some quarters and missed in others. The company beat expectations in the first quarter of 2026 but missed meaningfully in the second quarter, when a pre-launch surge in spending drove a wider-than-expected loss of $1.44 per share. As a result, investors will be watching whether the third quarter delivers more disciplined expense control and whether the early REVTORPYK launch trajectory validates the company's commercial infrastructure build-out.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking biotechnology names such as Celcuity around earnings events, the AI Screener offers a streamlined way to surface comparable companies and momentum signals.

Market Reaction and Investor Sentiment

Sentiment heading into the report is a balancing act between a historic product approval and the heavy spending required to support a launch. The stock has been volatile around recent earnings, reflecting how sensitive investors are to both the bottom line and forward commentary. The second quarter 2026 report triggered a negative reaction after the company missed estimates, highlighting that clinical success alone does not insulate the shares from concerns about rising costs. Heading into the third quarter release, investors will be weighing the first evidence of REVTORPYK commercial traction against the likelihood of another quarter of elevated operating expenses. Key risk factors include slower-than-expected launch uptake, higher-than-expected sales force and marketing costs, and any perceived delays in the supplemental regulatory path for PIK3CA-mutant patients.

Forward Outlook and Key Factors to Monitor

The most important item to monitor next is the commercial trajectory of REVTORPYK. Because the drug only began shipping late in the third quarter, revenue for this period may be modest, and investors should focus on management's commentary about prescription trends, payer coverage, and gross-to-net adjustments rather than the headline sales figure alone.

A second key factor is spending discipline. Celcuity's SG&A expenses surged as it built out a commercial organization, and R&D remains substantial across its breast cancer and prostate cancer programs. Whether the company can begin narrowing losses while scaling sales will be central to the stock's direction.

Regulatory milestones are also critical. The company plans a supplemental New Drug Application (sNDA) to expand the REVTORPYK label to PIK3CA-mutant patients, and early clinical data showed the gedatolisib-based regimens roughly doubling progression-free survival versus the existing standard of care. Progress on this filing could meaningfully expand the addressable market.

Finally, investors should watch for prostate cancer data expected in the fourth quarter. Positive results would broaden the pipeline beyond breast cancer and could support the long-term growth story. With cash of approximately $754 million expected to fund operations into 2029, the company has runway to execute, but disciplined capital allocation will remain a central focus.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations